UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/632,436	08/01/2003	Michael F. Thomashow	21835-00004	3828
23535 MEDLEN & CA	7590 03/05/200 ARROLL, LLP	EXAMINER		
101 HOWARD		KUMAR, VINOD		
SUITE 350 SAN FRANCIS	SCO, CA 94105		ART UNIT	PAPER NUMBER
			1638	
			MAIL DATE	DELIVERY MODE
			03/05/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
10/632,436	THOMASHOW ET AL.		
Examiner	Art Unit		
VINOD KUMAR	1638		

	VINOD KUMAR	1638	
The MAILING DATE of this communication appe	ars on the cover sheet with the c	orrespondence add	ress
THE REPLY FILED 13 February 2008 FAILS TO PLACE THIS	APPLICATION IN CONDITION FO	R ALLOWANCE.	
1. The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following rapplication in condition for allowance; (2) a Notice of Appe for Continued Examination (RCE) in compliance with 37 C periods:	eplies: (1) an amendment, affidavit al (with appeal fee) in compliance	t, or other evidence, www. with 37 CFR 41.31; or	hich places the (3) a Request
a) The period for reply expiresmonths from the mailing b) The period for reply expires on: (1) the mailing date of this Ac no event, however, will the statutory period for reply expire la Examiner Note: If box 1 is checked, check either box (a) or (I MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f	dvisory Action, or (2) the date set forth interthan SIX MONTHS from the mailing (b). ONLY CHECK BOX (b) WHEN THE	g date of the final rejection	n.
Extensions of time may be obtained under 37 CFR 1.136(a). The date of have been filed is the date for purposes of determining the period of extrunder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	on which the petition under 37 CFR 1.13 ension and the corresponding amount of hortened statutory period for reply origin	of the fee. The appropria nally set in the final Offic	ate extension fee e action; or (2) as
2. The Notice of Appeal was filed on A brief in compl filing the Notice of Appeal (37 CFR 41.37(a)), or any exter Notice of Appeal has been filed, any reply must be filed wi	sion thereof (37 CFR 41.37(e)), to	avoid dismissal of the	
3. The proposed amendment(s) filed after a final rejection, be (a) They raise new issues that would require further core (b) They raise the issue of new matter (see NOTE below (c) They are not deemed to place the application in bett appeal; and/or (d) They present additional claims without canceling a content of the second c	sideration and/or search (see NOT v); er form for appeal by materially rec	E below); lucing or simplifying tl	
NOTE: (See 37 CFR 1.116 and 41.33(a)). 4. The amendments are not in compliance with 37 CFR 1.12 5. Applicant's reply has overcome the following rejection(s): 6. Newly proposed or amended claim(s) would be all non-allowable claim(s).	11. See attached Notice of Non-Cor	mpliant Amendment (l	·
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is prove The status of the claim(s) is (or will be) as follows: Claim(s) allowed: None. Claim(s) objected to: Claim(s) rejected: 12,20-24 and 26-31. Claim(s) withdrawn from consideration: 9, 11, 17.		be entered and an ex	xplanation of
AFFIDAVIT OR OTHER EVIDENCE			
 The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e). 	sufficient reasons why the affidavi	t or other evidence is	necessary and
9. The affidavit or other evidence filed after the date of filing a entered because the affidavit or other evidence failed to or showing a good and sufficient reasons why it is necessary	vercome <u>all</u> rejections under appea	l and/or appellant fail:	s to provide a
10. \square The affidavit or other evidence is entered. An explanation	of the status of the claims after er	ntry is below or attach	ed.
REQUEST FOR RECONSIDERATION/OTHER 11. ☐ The request for reconsideration has been considered but See Continuation Sheet.	does NOT place the application in	condition for allowan	ce because:
12. ☐ Note the attached Information <i>Disclosure Statement</i> (s). (13. ☐ Other:	PTO/SB/08) Paper No(s)		
	/Phuong T. Bui/ Primary Examiner, Art U	nit 1638	

Continuation of 11. does NOT place the application in condition for allowance because: (a) It is noted that Applicant has not addressed new matter rejection in their response. Written description rejection for new matter is not addressed. It is also noted that amendments to claim 12 and 26 do not overcome new matter related issues, (b) Applicant has not presented new arguments to traverse 102(b) rejection on record. It is thus maintained that Harper et al. disclose a transgenic plant, and a method of producing said plant comprising transforming a plant cell or plant with a DNA expression cassette, comprising a promoter (constitutive, inducible or tissue-specific) operably linked to a coding sequence of SEQ ID NO: 2316 (encoding a DNA binding protein RAV1) which has 100% sequence identity to instant SEQ ID NO: 1. The reference further discloses that over-expression of SEQ ID NO: 2316 induces stress tolerance in said transgenic plant, and wherein said stress includes freezing, drought and other types of environmental stresses. Furthermore, reference also discloses method steps of selecting or screening transgenic plants comprising SEQ ID NO: 2316 with improved abiotic stress tolerance for cold or dehydration. See in particular, page 2, paragraph 0012 and 0017; page 3, paragraph 0020; page 7; paragraph 0039; page 12, paragraph 0067; page 13, paragraph 0079; page 18, paragraph 0109, Also see, page 5, paragraph 0031, page 10, paragraph 0054. Also see, claims 29, 33, 35, 46, 47, 49, 51, 52, 53 and 55. Furthermore, Harper et al. also disclose plant cells or tissues susceptible to infection with Agrobacterium tumefaciens that contain and express a chimeric gene comprising a promoter operably linked to SEQ ID No: 2316 which has 100% sequence identity to instant SEQ ID NO: 1. See page 24 and paragraph 0145. The property of binding to a CAACA sequence is inherent to the polypeptide encoded by the nucleotide sequence disclosed by Harper et al. This is also evidenced by Kagaya et al. (page 478, first and second paragraph). It must be noted that the property of regulating cold and dehydration genes in a plant is also inherent to Harper et al's method which comprises expressing SEQ ID NO: 2316 encoding a transcription regulating protein in a transgenic plant. As discussed in detail in previous Office actions, the property of cold or drought tolerance is also inherent to the method disclosed by Harper et al. which clearly disclose a method of making a stress tolerant transgenic plant using SEQ ID NO: 2316, and selecting said transgenic plant on an abiotic stress, such as cold, dehydration, salt, drought etc. Also see In re Cruciferous Sprout Litig., 301 F.3d 1343,1346-48, 64 USPQ2d 1202, 1204-05 (Fed. Cir. 2002) where a claim at issue was directed to a method of preparing a food rich in glucosinolates wherein cruciferous sprouts are harvested prior to the 2-leaf stage. The court held that the preamble phrase "rich in glucosinolates" helps define the claimed invention, as evidenced by the specification and prosecution history, and thus is a limitation of the claim (although the claim was anticipated by prior art that produced sprouts inherently "rich in glucosinolates"). Furthermore, see Integra LifeSciences I Ltd. V. Merck KGaA 50 USPQ2d 1846, 1850 (DC Scalif 1999), which teaches that where the prior art teaches all of the required steps to practice the claimed method and no additional manipulation is required to produce the claimed result, then prior art anticipates the claimed invention. Accordingly, the rejection is maintained.